Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $616 from $612 and keeps an Overweight rating on the shares. Q1 results were “uneventful” and FY26 guidance was reiterated, notes the analyst, who says that kidney pipeline execution remains the focus.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
- Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
- Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
- Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
- Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines